Michael Fumento

Mass hysteria is a poor method for allocating medical research resources. Surely we all agree on that in principle. But when it concerns any given hysteria, principle flies out the window.

Consider vaccine development efforts for the bacterium Methicillin resistant staphylococcus aureus, or MRSA, compared to that of three germs that have killed no Americans — indeed few non-Americans — yet prompted frenzies. These three include Ebola virus, SARS, and avian flu H5N1.

MRSA suddenly received widespread attention because of a report on its prevalence released in the October 17 issue of the Journal of the American Medical Association. It can cause infections in the bloodstream, lungs, and urinary tract.

Traditionally it has been associated with hospital surgical incisions, but as it becomes more common it's spreading beyond its normal breeding grounds.

According to the JAMA paper, prepared by the Centers for Disease Control and Prevention, there were more than 94,000 invasive MRSA infections in America in 2005, causing almost 19,000 deaths. Those figures appear to be increasing.

But while the JAMA findings were startling to the public, our public health authorities have long known of it – since 1961

in fact. Yet they’ve done very little about it.

Consider now the government reactions to the three mass hysteria diseases.The National Institutes of Health began a human clinical trial for the Ebola virus almost four years ago. Clinical trials for SARS (Severe Acute Respiratory Syndrome) began almost three years ago. Both vaccines were developed by and are being tested by the U.S. government. Your tax dollars also paid for the development of the first approved human avian flu vaccine that the government is stockpiling.

Michael Fumento

Michael Fumento is a, journalist, and attorney specializing in science and health issues as well as author of BioEvolution: How Biotechnology is Changing Our World .

Be the first to read Michael Fumento's column. Sign up today and receive Townhall.com delivered each morning to your inbox.